The lead compounds in Figure 5C are being optimized through extensive medicinal chemistry in our laboratory to yield a clinical candidate for HER2 antibody–resistant breast cancer, supported by the California-based biotech, Anviron. This evidence concerns the gene ERBB2 and breast carcinoma.